期刊文献+

西妥昔单抗联合FOLFIRI方案治疗转移性大肠癌病人的观察与护理 被引量:1

Observation and nursing care of cetuximab combined with FOLFIRI to treat patients with metastatic colorectal cancer
下载PDF
导出
摘要 [目的]总结西妥昔单抗联合FOLFIRI方案治疗转移性大肠癌病人的观察与护理。[方法]对19例转移性大肠癌病人行西妥昔单抗联合伊立替康(CPT-11)、氟尿嘧啶(5-FU)、亚叶酸钙(CF)组成的FOLFIRI方案治疗,同时加强心理护理、不良反应的护理等。[结果]19例病人发生胃肠道反应10例,骨髓抑制6例,粉刺样皮疹8例,延迟性腹泻4例,变态反应1例,乙酰胆碱能综合征3例,肛周脓肿1例;经过积极的预防、对症处理及护理干预,19例病人均顺利完成预定的治疗方案,无一例病人中止治疗。[结论]加强转移性大肠癌病人行西妥昔单抗联合FOLFIRI方案治疗的护理有利于治疗的顺利进行,提高治疗效果。 Objective:It summarized observation and nursing care of cetuximab combined with FOLFIRI to treat patients with metastatic colorectal cancer.Methods:A total of 19 patients with metastatic colorectal cancer accepted treatment protocols of cetuximab combined with FOLFIRI were selected and obseved.At the same time,all cases were given strengthened psychological care and nursing care of adverse reactions.Results:Totally 10 patients occurred with gastrointestinal reactions,6 cases were with bone marrow suppression,8 cases were with acne-like erythra,4 cases with delayed diarrhea,1 case with allergy,3 cases with acetylcholine syndrome and 1 case with perianal abscess.By active prevention,symptomatic treatment and nursing intervention,all 19 patients had completed the scheduled treatment successfully.Conclusion:To strengthen nursing care of cetuximab combined with FOLFIRI in treatment of patients with metastatic colorectal cancer is helpful for successful treatment.And it can enhance the treatment effectiveness of them as well.
作者 赵芳 韩雪
出处 《全科护理》 2011年第22期1982-1984,共3页 Chinese General Practice Nursing
关键词 转移性大肠癌 西妥昔单抗 FOLFIRI方案 不良反应 护理 metastatic colorectal cancer cetuximab FOLFIRI adverse reaction nursing care
  • 相关文献

参考文献9

  • 1Yerhardt JA,Mayer RJ.Systemic thempy for colorectal cancer[J].N Engl J Med,2005,352(5):476-487.
  • 2Mendelsohn J,Kawamoto T,Sato G,et al.Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor[J].United States Patent,1990,4:533-943.
  • 3Li S,Schmitz KR,Jeffrey PD,et al.Structural basis for inhibition of the epidermal growth factor receptor by cetuximab[J].Cancer Cell,2005,7:301-11.
  • 4Goldstein NI,Prewett M,Zuklys K,et al.Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model[J].Clin Cancer Res,1995,1:1311-1318.
  • 5孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.
  • 6David E.Cetuximab in metastatic colorectal cancer[J].London Cancer New Drugs Group-APC/DTC Briefing,2005,7(1):1-10.
  • 7David C,Yves H,Salvatore S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinoteean-refractory metastatic colorectal cancer[J].New Engl J Med,2004,351(4):337-345.
  • 8Huang SM,Boek JM,Harari PM.Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinorma of the head and neck[J].Cancer Res,1999,59:1935-1940.
  • 9Cunningham D,Humbley Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351(4):337-345.

共引文献302

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部